• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

采用新评分系统对ST段抬高型心肌梗死患者无复流及主要不良心血管事件的预测

Prediction of no-reflow and major adverse cardiovascular events with a new scoring system in STEMI patients.

作者信息

Bayramoğlu Adil, Taşolar Hakan, Kaya Ahmet, Tanboğa İbrahim Halil, Yaman Mehmet, Bektaş Osman, Günaydın Zeki Yüksel, Oduncu Vecih

机构信息

Department of Cardiology, Faculty of Medicine, Ordu University, Ordu, Turkey.

Department of Cardiology, Adiyaman University Training and Research Hospital, Adıyaman, Turkey.

出版信息

J Interv Cardiol. 2018 Apr;31(2):144-149. doi: 10.1111/joic.12463. Epub 2017 Nov 28.

DOI:10.1111/joic.12463
PMID:29193382
Abstract

BACKGROUND

No-reflow is associated with a poor prognosis in STEMI patients. There are many factors and mechanisms that contribute to the development of no-reflow, including age, reperfusion time, a high thrombus burden, Killip class, long stent use, ejection fraction ≤40, and a high Syntax score. In this study, we aimed to evaluate the parameters associated with no-reflow prediction by creating a new scoring system.

METHODS

The study included 515 consecutive STEMI patients who underwent PCI; 632 STEMI patients who had undergone PCI in another center were included in the external validation of the scoring system. The correlations between 1-year major adverse cardiac events and low/high risk score were assessed.

RESULTS

In this study, seven independent variables were used to build a risk score for predicting no-reflow. The predictors of no-reflow are age, EF ≤40, SS ≥22, stent length ≥20, thrombus grade ≥4, Killip class ≥3, and pain-balloon time ≥4 h. In the derivation group, the optimal threshold score for predicting no-reflow was >10, with a 75% sensitivity and 77.7% specificity (Area under the curve (AUC) = 0.809, 95%CI: 0.772-0.842, P < 0.001). In the validation group, AUC was 0.793 (95%CI: 0.760-0.824, P < 0.001).

CONCLUSION

This new score, which can be calculated in STEMI patients before PCI and used to predict no-reflow in STEMI patients, may help physicians to estimate the development of no-reflow in the pre-PCI period.

摘要

背景

无复流现象与ST段抬高型心肌梗死(STEMI)患者的不良预后相关。促成无复流现象发生的因素和机制众多,包括年龄、再灌注时间、高血栓负荷、Killip分级、长支架使用、射血分数≤40以及高Syntax评分。在本研究中,我们旨在通过创建一种新的评分系统来评估与无复流预测相关的参数。

方法

本研究纳入了515例连续接受经皮冠状动脉介入治疗(PCI)的STEMI患者;632例在另一个中心接受过PCI的STEMI患者被纳入评分系统的外部验证。评估了1年主要不良心脏事件与低/高风险评分之间的相关性。

结果

在本研究中,使用七个独立变量构建了预测无复流的风险评分。无复流的预测因素为年龄、射血分数≤40、Syntax评分≥22、支架长度≥20、血栓分级≥4、Killip分级≥3以及疼痛至球囊扩张时间≥4小时。在推导组中,预测无复流的最佳阈值评分为>10,敏感性为75%,特异性为77.7%(曲线下面积(AUC)=0.809,95%置信区间:0.772 - 0.842,P<0.001)。在验证组中,AUC为0.793(95%置信区间:0.760 - 0.824,P<0.001)。

结论

这种新的评分可在STEMI患者PCI术前计算得出,并用于预测STEMI患者的无复流现象,可能有助于医生在PCI术前评估无复流现象的发生情况。

相似文献

1
Prediction of no-reflow and major adverse cardiovascular events with a new scoring system in STEMI patients.采用新评分系统对ST段抬高型心肌梗死患者无复流及主要不良心血管事件的预测
J Interv Cardiol. 2018 Apr;31(2):144-149. doi: 10.1111/joic.12463. Epub 2017 Nov 28.
2
Plasma apelin-12 levels may predict in-hospital major adverse cardiac events in ST-elevation myocardial infarction and the relationship between apelin-12 and the neutrophil/lymphocyte ratio in patients undergoing primary coronary intervention.血浆apelin-12水平可能预测ST段抬高型心肌梗死患者住院期间的主要不良心脏事件以及接受直接冠状动脉介入治疗患者中apelin-12与中性粒细胞/淋巴细胞比值之间的关系。
Perfusion. 2017 Apr;32(3):206-213. doi: 10.1177/0267659116676335. Epub 2016 Oct 22.
3
Predictors of no-reflow phenomenon following percutaneous coronary intervention for ST-segment elevation myocardial infarction.经皮冠状动脉介入治疗 ST 段抬高型心肌梗死无复流现象的预测因素。
Ann Cardiol Angeiol (Paris). 2021 Jun;70(3):136-142. doi: 10.1016/j.ancard.2021.04.004. Epub 2021 May 4.
4
The relationship between neutrophil counts on admission and angiographic no-reflow after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction.ST段抬高型心肌梗死患者入院时中性粒细胞计数与直接经皮冠状动脉介入治疗后血管造影无复流之间的关系。
Acta Cardiol. 2016 Apr;71(2):241-6. doi: 10.2143/AC.71.2.3141856.
5
The Value of Pre-Infarction Angina and Plasma D-Dimer in Predicting No-Reflow After Primary Percutaneous Coronary Intervention in ST-Segment Elevation Acute Myocardial Infarction Patients.梗死后心绞痛和血浆 D-二聚体对 ST 段抬高型急性心肌梗死患者直接经皮冠状动脉介入治疗无复流的预测价值。
Med Sci Monit. 2018 Jul 1;24:4528-4535. doi: 10.12659/MSM.909360.
6
New CHADS-VASc-HSF score predicts the no-reflow phenomenon after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction.新型 CHADS-VASc-HSF 评分预测 ST 段抬高型心肌梗死患者行直接经皮冠状动脉介入治疗后无复流现象。
BMC Cardiovasc Disord. 2020 Jul 25;20(1):346. doi: 10.1186/s12872-020-01623-w.
7
Novel predictors and adverse long-term outcomes of No-reflow phenomenon in patients with acute ST elevation myocardial infarction undergoing primary percutaneous coronary intervention.急性 ST 段抬高型心肌梗死患者行直接经皮冠状动脉介入治疗后无复流现象的新预测因子及不良长期预后。
Indian Heart J. 2021 Jan-Feb;73(1):35-43. doi: 10.1016/j.ihj.2020.12.008. Epub 2020 Dec 29.
8
Development and validation of a clinical risk score predicting the no-reflow phenomenon in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction.预测ST段抬高型心肌梗死患者直接经皮冠状动脉介入治疗后无复流现象的临床风险评分的开发与验证
Cardiology. 2013;124(3):153-60. doi: 10.1159/000346386. Epub 2013 Mar 8.
9
Usefulness of Mean Platelet Volume-to-Lymphocyte Ratio for Predicting Angiographic No-Reflow and Short-Term Prognosis After Primary Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Myocardial Infarction.平均血小板体积与淋巴细胞比值对预测ST段抬高型心肌梗死患者直接经皮冠状动脉介入治疗后血管造影无复流及短期预后的价值
Am J Cardiol. 2017 Aug 15;120(4):534-541. doi: 10.1016/j.amjcard.2017.05.020. Epub 2017 May 30.
10
A risk score for no reflow in patients with ST-segment elevation myocardial infarction after primary percutaneous coronary intervention.直接经皮冠状动脉介入治疗后ST段抬高型心肌梗死患者无复流的风险评分
Clin Cardiol. 2015 Apr;38(4):208-15. doi: 10.1002/clc.22376. Epub 2015 Apr 16.

引用本文的文献

1
Accuracy of Machine Learning Models for Early Prediction of Major Cardiovascular Events Post Myocardial Infarction: A Systematic Review and Meta-Analysis.机器学习模型对心肌梗死后主要心血管事件早期预测的准确性:一项系统评价和荟萃分析
Rev Cardiovasc Med. 2025 Jun 17;26(6):37224. doi: 10.31083/RCM37224. eCollection 2025 Jun.
2
Predictive value of the CHA₂DS₂-VASc-HSF score for slow flow during rotational atherectomy in patients with severe coronary artery calcification.CHA₂DS₂-VASc-HSF评分对严重冠状动脉钙化患者旋磨术中慢血流的预测价值
BMC Cardiovasc Disord. 2025 Jul 4;25(1):469. doi: 10.1186/s12872-025-04931-1.
3
Predicting the no-reflow phenomenon in ST-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: a systematic review of clinical prediction models.
预测行直接经皮冠状动脉介入治疗的 ST 段抬高型心肌梗死患者无复流现象:临床预测模型的系统评价。
Ther Adv Cardiovasc Dis. 2024 Jan-Dec;18:17539447241290438. doi: 10.1177/17539447241290438.
4
Machine learning prediction of no reflow in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.对接受直接经皮冠状动脉介入治疗的ST段抬高型心肌梗死患者无复流的机器学习预测
Cardiovasc Diagn Ther. 2024 Aug 31;14(4):547-562. doi: 10.21037/cdt-24-83. Epub 2024 Aug 8.
5
Mechanisms and Definitions of Periprocedural Myocardial Infarction in the Era of Modern Revascularization.现代血运重建时代围手术期心肌梗死的机制与定义
Rev Cardiovasc Med. 2022 Oct 18;23(10):351. doi: 10.31083/j.rcm2310351. eCollection 2022 Oct.
6
A Prediction Nomogram for No-Reflow in Acute Myocardial Infarction Patients after Primary Percutaneous Coronary Intervention.急性心肌梗死患者直接经皮冠状动脉介入治疗后无复流的预测列线图
Rev Cardiovasc Med. 2024 Apr 30;25(5):151. doi: 10.31083/j.rcm2505151. eCollection 2024 May.
7
Canada acute coronary syndrome risk score predicts no-/slow-reflow in ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention.加拿大急性冠状动脉综合征风险评分可预测接受直接经皮冠状动脉介入治疗的ST段抬高型心肌梗死患者的无复流/慢血流情况。
Heliyon. 2023 Oct 20;9(11):e21276. doi: 10.1016/j.heliyon.2023.e21276. eCollection 2023 Nov.
8
[Clinical variables associated with no-reflow after percutaneous coronary intervention in ST-segment elevation myocardial infarction: Secondary analysis of the PERSTEMI I and II study].[ST段抬高型心肌梗死患者经皮冠状动脉介入治疗后无复流相关临床变量:PERSTEMI I和II研究的二次分析]
Arch Peru Cardiol Cir Cardiovasc. 2022 Dec 31;3(4):196-203. doi: 10.47487/apcyccv.v3i4.253. eCollection 2022 Oct-Dec.
9
Machine learning to predict no reflow and in-hospital mortality in patients with ST-segment elevation myocardial infarction that underwent primary percutaneous coronary intervention.机器学习预测行直接经皮冠状动脉介入治疗的 ST 段抬高型心肌梗死患者无复流和住院死亡率。
BMC Med Inform Decis Mak. 2022 Apr 24;22(1):109. doi: 10.1186/s12911-022-01853-2.
10
The Comparison between Two Risk Scores as for the Prediction of Coronary Microvascular Obstruction during Primary Percutaneous Intervention.两种风险评分在预测原发性经皮冠状动脉介入治疗中冠状动脉微血管阻塞的比较。
Arq Bras Cardiol. 2021 May;116(5):959-967. doi: 10.36660/abc.20200115.